研究报告 |
|
|
|
|
携带不同数量增强子的嵌合型肝脏特异性启动子的构建及其体外实验研究 |
李文博, 张伟峰, 陈胤伯, 王东阳, 张琛, 夏海滨 |
陕西师范大学生命科学学院 西安 710062 |
|
The Study on Construction of Chimeric Hepatocyte Specific Promoter with Different Amount of Enhancers and Its Experimental Investigation in Vitro |
LI Wen-bo, ZHANG Wei-feng, CHEN Yin-bo, WANG Dong-yang, ZHANG Chen, XIA Hai-bin |
Laboratory of Gene Therapy, College of Life Sciences, Shaanxi Normal University, Xi'an 710062, China |
引用本文:
李文博, 张伟峰, 陈胤伯, 王东阳, 张琛, 夏海滨. 携带不同数量增强子的嵌合型肝脏特异性启动子的构建及其体外实验研究[J]. 中国生物工程杂志, 2012, 32(01): 15-20.
LI Wen-bo, ZHANG Wei-feng, CHEN Yin-bo, WANG Dong-yang, ZHANG Chen, XIA Hai-bin. The Study on Construction of Chimeric Hepatocyte Specific Promoter with Different Amount of Enhancers and Its Experimental Investigation in Vitro. China Biotechnology, 2012, 32(01): 15-20.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/
或
https://manu60.magtech.com.cn/biotech/CN/Y2012/V32/I01/15
|
[1] Fukazawa T, Matsuoka J, Yamatsuji T, et al. Adenovirus-mediated cancer gene therapy and virotherapy. Int J Mol Med, 2010, 25(1):3-10.
[2] Ma X J, Huang R, Kuang A R. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Cancer Invest, 2009, 27(6):673-681.
[3] Thieringer F R, Maass T, Anthon B, et al. Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. Mol Carcinog, 2011 Jun 16.
[4] Cao X, Yang M, Wei R C, et al. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Ther, 2011, 18(8):765-777.
[5] Klutz K, Willhauck M J, Wunderlich N, et al. Sodium Iodide Symporter (NIS)-Mediated Radionuclide Therapy of Liver Cancer After Transcriptionally Targeted Intratumoral in Vivo NIS Gene Delivery. Hum Gene Ther,2011 Jun 28.
[6] Chen L, Zheng J, Zhang Y, et al. Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther, 2011, 19(8):1521-1528.
[7] Kim S I, Shin D, Lee H, et al. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol, 2009,50(3):479-488.
[8] Argyros O, Wong S P, Niceta M, et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther, 2008, 15(24):1593-1605.
[9] Lam P Y, Sia K C, Khong J H, et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther, 2007, 15(6):1129-1136.
[10] Miao C H, Ohashi K, Patijn G A, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther, 2000, 1(6):522-532.
[11] Kramer M G, Barajas M, Razquin N,et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther, 2003, 7(3):375-385.
[12] Mawatari F, Tsuruta S, Ido A,et al. Retrovirus-mediated gene therapy for hepatocellular carcinoma:selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter. Cancer Gene Ther, 1998, 5(5):301-306.
[13] Ishikawa H, Nakata K, Mawatari F, et al. Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter. Biochem Biophys Res Commun, 2001, 287(4):1034-1040.
[14] Kay M A, Li Q, Liu T J,et al. Hepatic gene therapy:persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum Gene Ther, 1992, 3(6):641-647.
[15] Hafenrichter D G, Wu X, Rettinger S D, et al. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood, 1994, 84(10):3394-3404.
[16] Lam P Y, Sia K C, Khong J H, et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther, 2007, 15(6):1129-1136.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|